The most interesting developments in drug therapy for adult ALL are occurring in two fields: (1) molecularly targeted therapies and (2) the use of antibodies, conjugated antibodies, or antibody constructs.
Thomas Burmeister, MD, PhD
Advertisement
Articles by Thomas Burmeister, MD, PhD
Advertisement
Latest Updated Articles
- ALL in Adults: How Can We Do Better?
Published: September 12th 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
3
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
